NASDAQ · Biotechnology

Fate Therapeutics, Inc. (FATE) Stock

$2.18 +2.35% NASDAQ: FATE Healthcare

Valuation

MetricValue
Price$2.18
Market Cap$254.10M
P/E Ratio-2.21
P/B Ratio1.82
P/S Ratio41.66
EPS (TTM)$-1.15
52-Week High$3.23
52-Week Low$0.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-65.08%
ROA-48.44%
ROCE-58.72%
Gross Margin-2100.00%
Operating Margin-2114.29%
Net Margin-20.57%
Debt/Equity0.49
Current Ratio5.81

Annual Financials (USD)

Metric20212022202320242025
Revenue$56.0M$96.0M$64.0M$14.0M$7.0M
Operating Profit$-217.0M$-308.0M$-191.0M$-210.0M$-148.0M
Net Profit$-212.0M$-282.0M$-161.0M$-186.0M$-136.0M
EPS$-2.24$-2.91$-1.64$-1.64$-1.15
Op Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$921.0M$706.0M$506.0M$441.0M$319.0M
Total Liabilities$243.0M$222.0M$138.0M$122.0M$112.0M
Cash$134.0M$61.0M$42.0M$36.0M$47.0M
Borrowings$115.0M$109.0M$104.0M$85.0M$78.0M

Latest News

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials Stocktwits · Jul 9, 2026 Sector Update: Healthcare Stocks Softer Late Afternoon MT Newswires · Jul 9, 2026 Sector Update: Healthcare MT Newswires · Jul 9, 2026 Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 MT Newswires · Jul 9, 2026 Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate GlobeNewswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-163.0M$-248.0M$-132.0M$-123.0M$-106.0M
Investing Cash Flow$-375.0M$131.0M$107.0M$11.0M$105.0M
Financing Cash Flow$41.0M$0$0$5.0M$5.0M
Net Cash Flow$-34.0M$-72.0M$-19.0M$-6.0M$11.0M
Free Cash Flow$-214.0M$-284.0M$-138.0M$-124.0M$-112.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA-2.68
FCF Yield-39.07%
Quick Ratio4.85
Interest Coverage0.00
Return 1Y96.88%
Return 3Y-41.53%
Return 5Y-96.10%

Ownership

Insiders Held1.17%
Institutions Held73.03%
Institutions Float Held73.89%
Institutional HolderSharesReport Date
Redmile Group, LLC12,872,9462026-03-31
Blackrock Inc.10,068,6142026-03-31
Vanguard Capital Management LLC4,192,0632026-03-31
Vanguard Portfolio Management LLC4,134,5852026-03-31
Acadian Asset Management. LLC4,120,2002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOSAcumen Pharmaceuticals, Inc. $2.14 +1.90% -1.24 $154.57M 0.00%
ALECAlector, Inc. $2.08 +2.97% -1.84 $230.93M 0.00%
CRBPCorbus Pharmaceuticals Holdings, Inc. $5.38 +2.09% -0.95 $99.68M 0.00%
INOInovio Pharmaceuticals, Inc. $1.15 +5.50% -1.00 $79.46M 0.00%
MOLNMolecular Partners AG $3.91 -2.25% -2.08 $146.67M 0.00%

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is led by CEO Bahram Valamehr, employs 181 people, headquartered in US, publicly traded since 2013.

Fate Therapeutics, Inc. (FATE) stock trades at $2.18 with a market capitalization of $254.10M. The stock is valued at a price-to-earnings (P/E) ratio of -2.21, price-to-book of 1.82, price-to-sales of 41.66. Over the past 52 weeks the stock has ranged between $0.95 and $3.23, and currently trades 32.5% below its 52-week high.

On profitability, Fate Therapeutics, Inc. generates a return on equity (ROE) of -65.08%, return on capital employed of -58.72%, an operating margin of -2114.29%, a net profit margin of -20.57%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides